Trevor Langley

Part of Charles River Laboratories International, Inc., CRL Group France SAS is an investment holding French company. The company is based in Miserey, France. The CEOs are Aidan John Synnott and John Curtin. The company was founded in 2002.

Charles River Discovery Research Services UK Ltd. provides drug discovery products and services to various pharmaceutical companies. It focuses on three areas such as kinases, G-protein coupled receptors, and ion channels. The company was founded in 1997 and is headquartered in Kent, the United Kingdom.

Part of Charles River Laboratories International, Inc., Argenta Discovery 2009 Ltd. offers contract research drug discovery services. The company is based in Margate, UK.

Part of Charles River Laboratories International, Inc., BioFocus DPI (Holdings) Ltd. functions as an investment holding British company. The company is based in Margate, UK.

Greenstar Associates LLP provides investment services.

Part of Greenstar Associates LLP, Greenstar Resources Ltd. provides investment services in the agricultural industry. The company is based in Haywards Heath, UK.

Carcinotech Ltd. manufactures 3D printed mini tumors using patient-specific cancer stem cells, primary cells, and established cell lines. The company is based in Edinburgh, UK. The British company was founded in 2018 by Ishani Malhotra, who has been the CEO since 2018.

Charles River Discovery Research Services Finland Oy provides non-clinical central nervous system services to the pharmaceutical and biotechnology industries. The company was founded in 1998 and is located in Kuopio, Finland.

Medicines Discovery Catapult Ltd. is a not-for-profit organization that enables the community to accelerate innovative drug discovery. The private company is based in Macclesfield, UK, and has subsidiaries in the United Kingdom. The British company focuses on pioneering the next generation of medicine discovery techniques and technologies by validating new ways of discovering medicines and driving key talent and expertise across the sector. The CEO of the company is Chris Molloy.

Part of Charles River Laboratories International, Inc., Charles River Laboratories France Safety Assessment SAS engages in research and development in physical and natural sciences. The company is based in Saint-Germain-Nuelles, France. The French company was founded in 1982. The CEO is Brian Bathgate.

Part of Charles River Laboratories International, Inc., Charles River Laboratories Evreux SAS engages in research and development in other physical and natural sciences. The company is based in Miserey, France. The CEO of the French company is Olivier Foulon.

Strathdon Investments Ltd. invests in companies located in the United Kingdom. The fund targets companies operating in the fields of information technology, energy, finance, healthcare and process control sectors. It provides financing for startups and buyout capital with an investment size £50K and £2m.

LINC Scotland provides financial support services. It supports the emergence and formation of structured business angel syndicates. The company was founded in 1993 and is headquartered in Glasgow, the United Kingdom.

Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ.

Mann Bioinvest Ltd. invests in the life science sector. The company was founded by James Mellon in 2012 and is headquartered in Douglas, the United Kingdom.

NextPharma Technologies, In. develops, manufactures, packages, and distributes pharmaceutical products and formulations. The firm focuses on lyophilization, sterile fill finish and pellet technologies, and in product manufacturing including cyotoxics, hormones, penicillins, cephalosporins, and controlled drugs. The company was established on October 27, 2000 and is headquartered in London, the United Kingdom.

Part of UCB SA, UCB Celltech is a British company that develops novel therapeutic products for humans. The company is based in Slough, UK and was founded in 2006.

JPT Peptide Technologies GmbH provides innovative peptide based products and services for vaccine development, immune monitoring and peptide biomarker discovery. The firm’s products include custom peptides, modified & labeled peptides, clinical peptides, stable isotope-labeled peptides, SPOT peptides, immunogenic peptides, peptide libraries, peptide pools, peptide microarrays, peptide ELISA, enzyme profiling and epitope discovery service. The company was founded in 2004 and is headquartered in Berlin, Germany.

Part of UDG Healthcare Ltd. (Dublin), PHMR Ltd. is a healthcare consulting British company that specializes in insight-enabled pricing and market access approaches to ensure successful product launch and life-cycle management. The company is based in London, UK. The company helps its clients in the healthcare industries build value for their products by using academically-proven analytical methods to find and form clinical, economic, and humanistic evidence. PHMR is an international team of highly qualified health economists and research scientists. The company was founded by Mark Ratcliffe, who has been the CEO since incorporation. PHMR was acquired by UDG Healthcare Ltd. (Dublin) on January 26, 2021 for $43.75 million.

Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023.

Wyvern Asset Management Ltd. (Wyvern Asset Management) is an independent venture capital firm founded in 1999. The firm is headquartered in Bristol, United Kingdom.

Barwell Plc. provides investment and financial management services. It is a private equity and venture capital firm specializing in incubation, seed, start-up, and early stage financing. The firm prefers to invest in life sciences, software, oil and gas, water, and other sectors. The company was founded in 1993 and is headquartered in Glasgow, the United Kingdom

Azellon Ltd. develops stem cell therapy for the repair of avascular meniscal tears. The firm's meniscal repair technology combines bone marrow stem cells with a special membrane that helps to deliver the cells into the injured site. The company was founded by Anthony Hollander and Troels Jordansen in 2007 and is headquartered in London, the United Kingdom.